Biocancer

Bio-Cancer Treatment International (BCT) is a clinical-stage biopharmaceutical company headquartered in Hong Kong, focused on the research and development of innovative biologics for human malignancies and autoimmune disorders. The company's core technology centers on arginine depletion therapy, which targets arginine-auxotrophic cancers that lack the ability to synthesize arginine internally. BCT's lead candidate, BCT-100 (pegylated recombinant human arginase 1), is currently in Phase 2 clinical trials for indications such as hepatocellular carcinoma (HCC) and acute myeloid leukemia (AML). BCT has established partnerships with organizations like I-Mab Biopharma to explore the potential of its arginine-depleting agents in broader therapeutic contexts.